A novel pharmaceutical composition for treating metabolic syndrome and diseases related thereto

摘要

The present invention relates to a novel pharmaceutical composition for the treatment of nonalcoholic fatty liver or nonalcoholic steatohepatitis, and more particularly, a first fusion protein in which a GLP-1 analogue is linked to an antibody Fc region and a GLP-2 analogue linked to an antibody Fc region It relates to a pharmaceutical composition for treating metabolic syndrome and diseases related thereto, comprising a second fusion protein, and comprising, as an active ingredient, a dual specificity fusion protein produced by dimerization of the first fusion protein and the second fusion protein. .